Horizon Therapeutics PLC
Change company Symbol lookup
Select an option...
HZNP Horizon Therapeutics PLC
SCL Stepan Co
GRWG GrowGeneration Corp
ROG Rogers Corp
ALB Albemarle Corp
DD Dupont De Nemours Inc
SMG Scotts Miracle-Gro Co
MTX Minerals Technologies Inc
HUN Huntsman Corp
PPG PPG Industries Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Based in Ireland
Company profile

Horizon Therapeutics plc is a global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. The Company operates through two segments: orphan segment and the inflammation segment. The orphan segment includes medicines, such as TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase injection), RAVICTI (glycerol phenylbutyrate), PROCYSBI (cysteamine bitartrate), UPLIZNA (inebilizumab-cdon) injection, ACTIMMUNE (interferon gamma-1b) injection, BUPHENYL (sodium phenylbutyrate) tablets and powder, and QUINSAIR (levofloxacin) solution. The inflammation segment includes medicines, such as PENNSAID (diclofenac sodium topical solution), RAYOS (prednisone), VIMOVO (naproxen), and DUEXIS (ibuprofen).

Closing Price
$78.28
Day's Change
0.75 (0.97%)
Bid
--
Ask
--
B/A Size
--
Day's High
78.45
Day's Low
77.56
Volume
(Light)
Volume:
534,719

10-day average volume:
1,658,583
534,719

Display:

Providers:

UpdateCancel
6 providers
November 23, 2022
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect(TM) Formulation of Teprotumumab

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered...(BusinessWire)

November 16, 2022
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA(R) (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed enrollment of its Phase 3 clinical trial (OPTIC-J) in Japan evaluating TEPEZZA for the treatment of active Thyroid Eye Disease (TED). (BusinessWire)

Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation

Horizon Therapeutics plc today announced that it has entered a multi-year scientific collaboration with Johns Hopkins University School of Medicine to identify new disease targets and develop therapies for patients with serious autoimmune and...(BusinessWire)

November 10, 2022
Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in November: Stifel 2022 Healthcare Conference Date: Tuesday, Nov. 15, 2022 Presentation Time: 1:15 p.m. ET Location: New...(BusinessWire)

November 08, 2022
Sustained Patient Response to KRYSTEXXA(R) (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial

-- Imaging analyses visualize impact of KRYSTEXXA with methotrexate on reducing uric acid deposits in the joints, with a 95% mean reduction over 52 weeks, as well as reductions in vascular inflammation -- (BusinessWire)

November 05, 2022
Data Support the Use of KRYSTEXXA(R) (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate KRYSTEXXA (pegloticase) injection with weekly oral methotrexate effectively treats uncontrolled gout without compromising kidney function. These findings are presented as...(BusinessWire)

November 02, 2022
Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations

--Full-Year 2022 Guidance and Peak Annual Net Sales Expectations: -- Increasing Full-Year 2022 Net Sales Guidance to $3.59 Billion to $3.61 Billion -- -- Increasing Full-Year 2022 Adjusted EBITDA Guidance to $1.32 Billion to $1.34 Billion, Which...(BusinessWire)

November 01, 2022
Horizon Therapeutics plc Named to the Seramount Inclusion Index

Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named to Seramount's (formerly Working Mother media) 2022 Inclusion Index. The Inclusion Index recognizes companies that commit to advancing diversity, equity and inclusion (DEI)...(BusinessWire)

October 27, 2022
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind...(PR Newswire)

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind...(BusinessWire)

October 26, 2022
New Analysis of UPLIZNA(R) (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from two analyses of the UPLIZNA Phase 3 pivotal trial being presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022)...(BusinessWire)

October 22, 2022
New Real-World Analysis of TEPEZZA(R) (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from a real-world analysis of TEPEZZA presented at the 91st Annual Meeting of the ATA. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA)...(BusinessWire)

October 13, 2022
Horizon Therapeutics plc to Present New Data on TEPEZZA(R) (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting

-- Poster presentation on inflammatory TED to discuss impact on patients throughout the course of disease -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid...(BusinessWire)

October 12, 2022
Horizon Therapeutics plc Announces New UPLIZNA(R) (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022, Oct. 26-28. UPLIZNA is the first and...(BusinessWire)

October 06, 2022
Horizon Therapeutics plc Named to Newsweek's 2022 Top 100 Most Loved Workplaces

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to Newsweek's 2022 Top 100 Most Loved Workplaces(R) list for prioritizing respect, caring and appreciation for employees. The Newsweek list is the result of a...(BusinessWire)

Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its third-quarter 2022 financial results on Wednesday, Nov. 2, 2022. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to...(BusinessWire)

October 02, 2022
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 (IGF-1) in patients with low CAS. These data were presented...(BusinessWire)

September 29, 2022
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA(R) (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS)...(BusinessWire)

September 22, 2022
Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner

Horizon Therapeutics plc (Nasdaq: HZNP) today expanded its commitment to education equity, science, technology, engineering, arts and math (STEAM) careers and historically Black colleges and universities (HBCUs) through its Horizon Scholars program...(BusinessWire)

September 21, 2022
Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve

Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is proud to announce the winning solution of this year's Horizon Prize: Patient-Driven Data Platform for Rare Disease by EB...(BusinessWire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.